PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Etoposide

Drugs in development · updated 30 October 2026

Etoposide: clinical trials and development status

Other names and codes: Avopef, Etopophos Preservative Free, Vepesid

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Etoposide is in 296 active clinical trials (recruiting or ongoing, phases I–III) for 141 diseases. The most advanced phase is III.

296Active trials
IIIMost advanced phase
141Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Etoposide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 141 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Lung small cell carcinomaIII54NCT07802821
Lung neoplasmIII20NCT04092283
Diffuse large B-cell lymphomaIII19NCT06792253
Precursor lymphoblastic lymphoma/leukemiaIII16NCT03007147
Burkitt lymphomaIII15NCT02101853
Acute myeloid leukemiaIII14NCT04293562
Hodgkin lymphomaIII12NCT04638790
B-cell lymphomaIII10NCT06230224
Non-Hodgkin lymphomaIII10NCT06230224
Germ cell and embryonal neoplasmsIII9NCT02582697
LymphomaII–III9NCT03117751
Non-small-cell lung carcinomaIII9NCT04092283
NeuroblastomaIII8NCT06172296
Multiple myelomaIII7NCT00572169
NeoplasmII–III6NCT01064466
Precursor T-cell lymphoblastic leukemiaIII6NCT02112916
GlioblastomaII–III5NCT06105619
Myelodysplastic SyndromesIII5NCT02521493
Ewing sarcomaIII4NCT02306161
Hemophagocytic lymphohistiocytosisIII4NCT07497438
Neuroendocrine carcinomaIII4NCT07833839
OsteosarcomaIII4NCT00470223
Ovarian neoplasmIII4NCT02429700
RetinoblastomaII–III4NCT04681417
GanglioneuroblastomaIII3NCT06172296
LeukemiaII–III3NCT03117751
SarcomaIII3NCT00470223
SeminomaIII3NCT02375204
TeratomaIII3NCT03067181
Acute biphenotypic leukaemiaIII2NCT03007147

Everything on Etoposide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch